Based in the United States, EvolveImmune is a startup.
EvolveImmune develops trispecific T cell engager therapies with integrated CD2 costimulation to address resistance in cancer immunotherapy, advancing a lead candidate EVOLVE104 into clinical trials.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.